Summit Therapeutics Inc.
$13.66 -$1.32 (-8.81%) 1D After hoursKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 23
A material event was filed (Form 8-K).
8-K - Summit Therapeutics Inc. (0001599298) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 23
Offering paper hit the record (Form 424B5).
424B5 - Summit Therapeutics Inc. (0001599298) (Filer)
RECEIPT: SEC FORM 424B5, TIMESTAMPED -
Jul 22
A material event was filed (Form 8-K).
8-K - Summit Therapeutics Inc. (0001599298) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Jun 10
From its Apr 21 high, the share price fell 51%.
Peak close $26.38 on Apr 21; trough close $13.05 on Jun 10. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -51% -
May 1
The stock moved -24.9% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, May 1 -
Apr 16
The stock moved +15.6% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Apr 16
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Summit Therapeutics Inc.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.